BioIntelliSense showcased their BioButton at the Consumer Electronics Show (CES) - which is being held virtually this year due to the global health crisis - on Monday (11.01.21), with the penny-sized device worn on the body to monitor temperature, respiratory rate and heartbeats in real time in order to check for early signs of the illness.
The medical-grade single-use device - which has been FDA approved - provides continuous monitoring for up to 90 days to give daily health screening results and determine a user's risk status by analysing the data it collects and highlighting any statistically meaningful changes in vital signs.
It can also detect activity level and body position measurements.
The BioButton connects to a smartphone via Bluetooth and the BioMobile app, with the app then giving a 'Cleared' or 'Not Cleared' notification after filling out a survey and analysing the vital information uploaded to the app from the device.
James Mault, MD, CEO of BioIntelliSense, said: "We are extremely honored to be named Best of Innovation as a CES 2021 Innovation Award honouree.
"The commercial launch of the BioButton COVID-19 symptom screening and vaccine monitoring solution is timely in addressing the growing challenge of safe return to worksites, school, travel, conferences and entertainment.
"The BioButton is the newest addition to our biosensor portfolio and data services model for public health and clinical applications that span infectious disease, orthopedics, oncology, and cardiac care."
Other pandemic-related tech on display at the event included smart masks that measure air quality and a keyboard light that promises to kill up to 99.9 percent of viruses and bacteria.